Skip to main content

O'Melveny & Myers, Tian Yuan Law Firm and William Ji & Co. have represented China’s Simcere Pharmaceutical Group on its HK$3.57 billion ($460.6 million) Hong Kong IPO, with Herbert Smith Freehills and Jingtian & Gongcheng advising the joint sponsors.

The listing is the latest by a Chinese biopharmaceutical company in Hong Kong, which is on track to have its second-busiest year for equity capital markets ever in 2020. Recent such issuers include JHBP (CY) Holdings and Everest Medicines.

Simcere Pharmaceutical supplies branded generic pharmaceuticals to the Chinese market. It has increased investment in R&D in recent years, and has three R&D centres in Nanjing, Shanghai and Boston.

Partners Matt Emsley, Siddhartha Sivaramakrishnan and Stanley Xie led the Herbert Smith Freehills team.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com. 

Related Articles

Deals

Top international firms act on landmark $7.1 bln ESR take-private deal

by Nimitt Dixit |

Global law firms Freshfields, Latham & Watkins, Kirkland & Ellis, Paul, Weiss, Rifkind, Wharton & Garrison and Cleary Gottlieb Steen & Hamilton have steered an offer to take the Hong Kong-listed ESR Group private in a deal valued at $7.1 billion.

Deals

Fangda, KWM act on HKAA’s $592 mln acquisition of Zhuhai Airport stake

by Hu Yangxiaoxiao 胡阳潇潇 |

Fangda Partners has advised the Hong Kong Airport Authority (HKAA) on its agreement to purchase a 35 percent stake in Zhuhai Airport for approximately $592 million, with King & Wood Mallesons representing the seller, Zhuhai Transportation.

Deals

BKL, Yoon & Yang guide $640 mln Korean real estate deal

by Nimitt Dixit |

Top South Korean firms Bae, Kim & Lee and Yoon & Yang have advised the seller and buyer, respectively, in the acquisition of Donuimun D Tower in central Seoul by NH Nonghyup REITs Management for $640 million from Mastern Asset Management.